The result was similar to that reported by Schapira et al. (2018), who found that the concurrent treatment of PD-1 inhibitors and radiotherapy improved the OS (median OS 17.6 months) and locoregional disease control of NSCLC patients with BMs. Here, PDCD1 is linked to non-small cell lung carcinoma.